47 reports

  • 5.1 VOLUME SHARE - (BREAST, COLORECTAL, PROSTATE) ONCOLOGY TEST

In addition, a project has been introduced into urban areas in China from 2012 and targets screening for lung cancer, breast cancer, colorectal cancer, upper gastrointestinal cancer and liver cancer.

  • Breast Cancer
  • Prostate Cancer
  • Asia
  • China
  • OriGene Technologies, Inc.

AstraZeneca engages in the R& D, manufacturing, and distribution of drugs for the treatment of respiratory diseases, inflammation, and autoimmunity disorders and infections; oncology diseases; cardiovascular and metabolic diseases; neurological diseases, and gastrointestinal diseases.

  • Prostate Cancer
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Sanofi S.A.

These areas include some of the world' s most serious illnesses and together represent a major worldwide burden of disease: cancer, cardiovascular, gastrointestinal, infection, neuroscience and respiratory & inflammation.

  • Prostate Cancer
  • China
  • AstraZeneca Pharmaceutical Co., Ltd
  • Bristol-Myers Squibb Company
  • Zhejiang Xianju Pharmaceutical Co., Ltd

These areas include some of the world' s most serious illnesses and together represent a major worldwide burden of disease: cancer, cardiovascular, gastrointestinal, infection, neuroscience and respiratory & inflammation.

  • Prostate Cancer
  • China
  • AstraZeneca Pharmaceutical Co., Ltd
  • Bristol-Myers Squibb Company
  • Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.

The double-balloon " push-pull" technique allows visualization and biopsy of the entire gastrointestinal tract.

  • Prostate Cancer
  • United States
  • Market Size
  • Illumina, Inc.
  • Trovagene, Inc.

The double-balloon " push-pull" technique allows visualization and biopsy of the entire gastrointestinal tract.

  • Prostate Cancer
  • United States
  • Market Size
  • Illumina, Inc.
  • Trovagene, Inc.
  • PROSTATE CANCER THERAPEUTICS, GLOBAL, ARN-509 REVENUE FORECAST ($M), 2020-

Despite this, development is still being pursued for the treatment of lymphomas, gastrointestinal cancer, metastatic breast cancer and PC.

  • Prostate Cancer
  • World
  • Merck & Co., Inc.
  • Novartis AG
  • PROVENGE group
  • J&J'S PROSTATE CANCER PORTFOLIO ASSESSMENT, 2014
  • PROVIDES AN ASSESSMENT OF J&J'S PROSTATE CANCER PORTFOLIO.

IT ALSO COMES WITH A WARNING REGARDING GASTROINTESTINAL (GI) SYMPTOMS, INCLUDING NAUSEA, VOMITING, AND DIARRHEA, AS WELL AS RENAL FAILURE, AND IS NOT RECOMMENDED FOR USE IN PATIENTS WITH IMPAIRED HEPATIC FUNCTION (JEVTANA PACKAGE INSERT, 2014).

  • Prostate Cancer
  • World
  • Astellas Pharma Inc.
  • GlobalData's company
  • PROVENGE group
  • J&J'S PROSTATE CANCER PORTFOLIO ASSESSMENT, 2014
  • provides an assessment of J&J's prostate cancer portfolio.

gastrointestinal stromal tumors).

  • Prostate Cancer
  • Forecast
  • Astellas Pharma Inc.
  • Bayer AG
  • PROVENGE group

IT ALSO COMES WITH A WARNING REGARDING GASTROINTESTINAL (GI) SYMPTOMS, INCLUDING NAUSEA, VOMITING, AND DIARRHEA, AS WELL AS RENAL FAILURE, AND IS NOT RECOMMENDED FOR USE IN PATIENTS WITH IMPAIRED HEPATIC FUNCTION (JEVTANA PACKAGE INSERT, 2014).

  • Prostate Cancer
  • World
  • Astellas Pharma Inc.
  • OncoGenex Pharmaceuticals, Inc.
  • PROVENGE group

IT ALSO COMES WITH A WARNING REGARDING GASTROINTESTINAL (GI) SYMPTOMS, INCLUDING NAUSEA, VOMITING, AND DIARRHEA, AS WELL AS RENAL FAILURE, AND IS NOT RECOMMENDED FOR USE IN PATIENTS WITH IMPAIRED HEPATIC FUNCTION (JEVTANA PACKAGE INSERT, 2014).

  • Prostate Cancer
  • World
  • Astellas Pharma Inc.
  • OncoGenex Pharmaceuticals, Inc.
  • PROVENGE group

Of note, gastrointestinal side effects were reported less frequently in elderly patients than in younger ones.

  • Clinical Trial
  • Healthcare
  • Prostate Cancer
  • United States
  • GlobalData's company
  • DORMANT PROJECTS (CONTD..1), H1 2016

IB-##C## - DRUG PROFILE MONOCLONAL ANTIBODY TO INHIBIT IL-## AND IL-## FOR ONCOLOGY, CENTRAL NERVOUS SYSTEM AND GASTROINTESTINAL DISORDERS - DRUG PROFILE PROSTATAC - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description Prostatac On

  • Hospital
  • Prostate Cancer
  • United States
  • World
  • Product Initiative

The drug candidate is expected to decrease the constipating effects of opioid pain medications in the gastrointestinal tract without affecting their ability to relieve pain.

  • Pharmaceutical
  • Prostate Cancer
  • United States
  • Company
  • Progenics Pharmaceuticals, Inc.
  • MEDIGENE AG - PIPELINE BY INDICATION, 2016

This report is a licensed product and is not to be photocopied MediGene AG has promising clinical drug candidates for ## major therapeutic areas, Gastrointestinal, Infectious Disease, Oncology and Immunology.

  • Cell Therapy
  • Leukemia
  • Prostate Cancer
  • Therapy
  • Medigene AG

Report covers products from therapy areas Oncology, Respiratory, Toxicology, Central Nervous System, Dermatology, Gastrointestinal and Infectious Disease which include indications Prostate Cancer, Colorectal Cancer, Lung Disease, Melanoma, Radiation Toxicity (Radiation Sickness, Acute Radia

  • Blood Supply
  • Prostate Cancer
  • Therapy
  • Vaccine
  • OncBioMune Pharmaceuticals, Inc.

Report covers products from therapy areas Oncology, Respiratory, Toxicology, Central Nervous System, Dermatology, Gastrointestinal, Hematological Disorders and Infectious Disease which include indications Melanoma, Colorectal Cancer, Lung Disease, Prostate Cancer, Radiation Toxicity (Radiat

  • Blood Supply
  • Cancer
  • Prostate Cancer
  • Therapy
  • OncBioMune Pharmaceuticals, Inc.

The Flexible Ablation System is anticipated to have multiple future applications in pulmonary, pancreatic and gastrointestinal fields.

  • Cancer
  • Clinical Trial
  • Prostate Cancer
  • United States
  • GlobalData's company

The most frequent side effects observed in patients treated with AT-## revolved around problems with the gastrointestinal tract, such as nausea, vomiting, and/ or sluggish bowel function.

  • Prostate Cancer
  • Therapy
  • United States
  • Product Initiative
  • AbbVie Inc.
  • QUEST PHARMATECH INC. - PIPELINE BY INDICATION, 2015
  • Phase I - Trial Details

SL-## Product Description SL-## is under development for the treatment of prostate cancer, benign prostatic hyperplasia (BPH), bladder cancer and gastrointestinal cancer.

  • Monoclonal Antibody
  • Prostate Cancer
  • R&D
  • Product Initiative
  • Quest PharmaTech Inc.

Bostwick also offers subspecialty laboratory services such as dermatopathology, gastrointestinal pathology, gynecologic pathology, hematopathology, renal pathology, culture and susceptibility testing, molecular testing, and uroregistry, among others.

  • Biopsy
  • Hospital
  • Prostate Cancer
  • United States
  • GenomeDx Biosciences Inc.

The company' s franchise areas in research include neurology, oncology, vascular and immunological reaction, gastrointestinal disorders, and musculoskeletal diseases.

  • Prostate Cancer
  • Vaccine
  • United States
  • World
  • Product Initiative
  • Application
  • METABOLOMIC TECHNOLOGIES INC PIPELINE PRODUCTS & ONGOING CLINICAL TRIALS OVERVIEW

Its products develop advanced diagnostic tests for gastrointestinal diseases in their early stages.

  • Clinical Trial
  • Pharmaceutical
  • Prostate Cancer
  • United States
  • GlobalData's company
  • 5. All the trials included are unique trials.

Gastrointestinal Tumors Efficacy of Radiotherapy in Combination with Zoledronic Acid in Bone Metastasis Patients with Gastrointestinal Tumors GDCT## NCT##, ##-2014-## Oncology Anal Cancer, Bone Metastasis, Colorectal Cancer, Esophageal Cancer, Gallbladder Cancer,

  • Cancer
  • Prostate Cancer
  • World
  • Product Initiative
  • Novartis AG
  • METASTATIC HORMONE REFRACTORY (CASTRATION RESISTANT, ANDROGEN-INDEPENDENT) PROSTATE CANCER - PIPELINE BY PFIZER INC., H1 2016
  • METASTATIC HORMONE REFRACTORY (CASTRATION RESISTANT, ANDROGEN-INDEPENDENT) PROSTATE CANCER - PIPELINE BY GLAXOSMITHKLINE PLC, H1 2016

The data were presented at the 2016 Gastrointestinal Cancers Symposium (ASCO GI).

  • Chemotherapy
  • Prostate Cancer
  • United States
  • Company
  • Product Initiative
  • Phase I/II - Trial Details
  • AT-101 - DRUG PROFILE

The most frequent side effects observed in patients treated with AT-## revolved around problems with the gastrointestinal tract, such as nausea, vomiting, and/ or sluggish bowel function.

  • Chemotherapy
  • Prostate Cancer
  • Therapy
  • United States
  • Product Initiative
  • Clinical Trial
  • Hospital
  • Prostate Cancer
  • United States
  • GlobalData's company

Report covers products from therapy areas Oncology, Immunology and Gastrointestinal which include indications Glioblastoma Multiforme (GBM), Inflammation, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Colorectal Cancer, Inflammatory Bowel Disease, Mantle Cell

  • Prostate Cancer
  • Therapy
  • World
  • Product Initiative
  • IMMD
  • Clinical Trial profile. 413 Trial Title
  • Clinical Trial profile. 334 Trial Title

Gastrointestinal Tract Cancer, Graft Versus Host Disease (GVHD), Melanoma, Metastatic Breast Cancer, Metastatic Prostate Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Renal Cell Carcinoma, Solid Tumor Completed Phase II Interventional allogeneic lymphocytes Hadassah Medical Center ##

  • Cancer
  • Clinical Trial
  • Prostate Cancer
  • World
  • Product Initiative

BIOMERIEUX S. A.

  • Breast Cancer
  • Infectious Disease
  • Prostate Cancer
  • United States
  • bioMerieux S.A.